This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
4 - 6 June, 2024
Excel London Platinum Suite

George Wang, PhD
Vice President of Antibody Discovery at WuXi Biologics


Dr. George Wang, Vice President of Biologics Innovation & Discovery at WuXi Biologics, currently is responsible for Discovery and Preclinical Service, covering contract service of therapeutic proteins from concept to IND filing. Dr. Wang played various leadership roles since he joined WuXi Biologics in 2014, including managing material generation for over 300 discovery projects, initiating domain antibody group, and establishing several bispecific antibody platforms. He innovated the proprietary WuXiBody® bispecific antibody platform which has been licensed to 12 clients with over $500 million deal value.

Prior to joining WuXi Biologics, Dr. Wang worked at Bayer Healthcare for nine years as group head. He contributed to several global projects, including leading a project from target to clinical development. He also participated evaluation and license-in of new technologies. Before that, Dr. Wang worked as scientist at two biotech start-ups.

Dr. Wang has authored over 20 publications in peer-reviewed journals and is the lead inventor on over 40 patents and patent applications.

Dr. Wang obtained a Ph.D. in oncology from Peking University and an MBA from the University of California at Berkeley. He completed his post-doctoral training at Harvard Medical School.

Agenda Sessions

  • Discovery-stage Developability Assessment and Optimization of Antibody-derived Therapeutics